




**Keywords:** ; A

## Introduction

(CB) A CB, (D) CB, CB, CB, C<sup>a</sup>F I.



### References

1. Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H ,et al. (2011) Risperidone versus other atypical antipsychotics for schizophrenia . Cochrane Database Syst Rev 1: 6626.
2. Rothe PH, Heres S, Leucht S, (2018) Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method. Schizophr Res 193: 23-28
3. Carulla N, Zhou M, Giralt E, Robinson CV, Dobson CM, et al. (2010) Structure

and intermolecular dynamics of aggregates populated during amyloid fibril formation studied by hydrogen/deuterium exchange. *Acc Chem Res* 43: 1072-1079.

4. Sinnige T, Stroobants K, Dobson CM, Vendruscolo M (2020) Biophysical studies of protein misfolding and aggregation in in vivo models of Alzheimer's and Parkinson's disease. *Q Rev Biophys* 49: 22.
5. Butterfeld S, Hejjaoui M, Fauvet B, Awad L, Lashuel HA, et al. (2012) Chemical strategies for controlling protein folding and elucidating the molecular mechanisms of amyloid formation and toxicity. *J Mol Biol* 111: 82-106.
6. Cremades N, Dobson CM (2018) The contribution of biophysical and structural studies of protein self-assembly to the design of therapeutic strategies for amyloid diseases. *Neurobiol Dis* 109: 178-190.
7. Cheng B, Gong H, Xiao H, Petersen RB, Zheng L, et al. (2013 ) Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases. *Biochim Biophys Acta* 1830: 4860-4871.
8. Zaman M, Khan AN, Wahiduzzaman, Zakariya SM, Khan RH, et al. (2019) Protein misfolding, aggregation and mechanism of amyloid cytotoxicity: An pr56e079.